Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Santen Pharmaceutical Co (4536) Price & Analysis

4536 Stock Chart & Stats

¥1,789.50¥19.00(1.07%)
At close: 4:00 PM EDT
JPY 1,700JPY 1,800JPY 1,9003 Aug17 Aug31 Aug14 Sep28 Sep13 Oct26 Oct
Day’s Range
JPY 1,773.00 - JPY 1,798.00
52-Week Range
JPY 1,484.50 - JPY 2,254.00
Previous Close
JPY 1,770.50
Volume
125.80K
Average Volume (3M)
1.05M
Market Cap
JPY 574.81B
Enterprise Value
JPY 637.18B
Total Cash (Recent Filing)
JPY 78.26B
Total Debt (Recent Filing)
JPY 31.01B
Price to Earnings (P/E)
15.0
Beta
0.39
Next Earnings
Nov 05, 2026
EPS Estimate
31.24
Next Dividend Ex-Date
Mar 30, 2027
Dividend Yield
2.24%

Bulls Say, Bears Say

Bulls Say

Profitability Recovery

The strong recovery in profitability provides a more durable earnings base than the company had in 2023. Healthy operating and net margins, together with improved returns on equity, should support reinvestment, brand development, and resilience across the ophthalmology portfolio.

Conservative Balance Sheet

Very low leverage gives Santen substantial financial flexibility as it funds research, product lifecycle management, and international commercialization. A strong equity base also reduces dependence on borrowing and helps the company absorb earnings variability without excessive balance-sheet strain.

Positive Cash Generation

Positive operating and free cash flow demonstrate that Santen is converting a substantial portion of reported earnings into internally generated funds. This supports continued investment in ophthalmology products and provides capacity for capital allocation without relying heavily on external financing.

Bears Say

Weaker Cash Conversion

The gap between operating profit and cash generation indicates weaker cash conversion than ideal, while the decline from 2024–2025 suggests less consistent working-capital or earnings conversion. If sustained, this could constrain internally funded investment despite reported profitability.

Earnings Volatility

The prior-year loss and weak operating margin show that Santen’s earnings trajectory has not been consistently stable. Such volatility makes forward profit generation less predictable and may limit management’s ability to plan investment, dividends, and product expansion with confidence.

Limited Balance-Sheet Expansion

A balance sheet that has not clearly expanded over time may indicate that the company is not consistently building its asset and equity base alongside operations. This could limit the scale of future investment and leaves less evidence of sustained capital accumulation.

Santen Pharmaceutical Co News

4536 FAQ

What was Santen Pharmaceutical Co’s price range in the past 12 months?
Santen Pharmaceutical Co lowest stock price was ¥1484.50 and its highest was ¥2254.00 in the past 12 months.
What is Santen Pharmaceutical Co’s market cap?
Santen Pharmaceutical Co’s market cap is ¥574.81B.
When is Santen Pharmaceutical Co’s upcoming earnings report date?
Santen Pharmaceutical Co’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Santen Pharmaceutical Co’s earnings last quarter?
Santen Pharmaceutical Co released its earnings results on Aug 06, 2026. The company reported ¥22.38 earnings per share for the quarter, beating the consensus estimate of ¥21.266 by ¥1.114.
Is Santen Pharmaceutical Co overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Santen Pharmaceutical Co pay dividends?
Santen Pharmaceutical Co pays a Semiannually dividend of ¥21 which represents an annual dividend yield of 2.24%. See more information on Santen Pharmaceutical Co dividends here
What is Santen Pharmaceutical Co’s EPS estimate?
Santen Pharmaceutical Co’s EPS estimate is 31.24.
How many shares outstanding does Santen Pharmaceutical Co have?
Santen Pharmaceutical Co has 322,314,150 shares outstanding.
What happened to Santen Pharmaceutical Co’s price movement after its last earnings report?
Santen Pharmaceutical Co reported an EPS of ¥22.38 in its last earnings report, beating expectations of ¥21.266. Following the earnings report the stock price went up 1.105%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co?
Currently, no hedge funds are holding shares in JP:4536
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology